Posted On: 05/20/2014 1:26:45 PM
Post# of 102864
$PPCH Propanc Health Group Corporation (PPCH) ("Propanc Health Group," "Propanc" or "the Company"
, a developmental stage a healthcare company focused on new cancer treatments for patients with solid tumors, today announced its key strategic objectives for the development of its lead product, PRP. This Company is now refocusing the preferred route of administration to intravenous (I.V.) injection. They are now targeting 2015 to prepare for and initiate human trials in patients with advanced colorectal and/or pancreatic cancers.
Dr Kenyon, Chief Scientific Officer of Propanc Health Group, states, "After a detailed strategic review of our scientific and preclinical research, our development team determined I.V. injection as the preferred route of administration. This approach would be the best way to maximise results in future patient trials, by ensuring maximum exposure of the drug to the tumor site."
James Nathanielsz, Chief Executive Officer of Propanc Health Group, said, "We believe this will help us to improve the results already observed in a Compassionate Use Study conducted by Dr Kenyon at the Dove Clinic (UK). We were able to extend life in a number of terminally ill patients, free from the serious side effects normally observed during conventional treatment methods."
, a developmental stage a healthcare company focused on new cancer treatments for patients with solid tumors, today announced its key strategic objectives for the development of its lead product, PRP. This Company is now refocusing the preferred route of administration to intravenous (I.V.) injection. They are now targeting 2015 to prepare for and initiate human trials in patients with advanced colorectal and/or pancreatic cancers. Dr Kenyon, Chief Scientific Officer of Propanc Health Group, states, "After a detailed strategic review of our scientific and preclinical research, our development team determined I.V. injection as the preferred route of administration. This approach would be the best way to maximise results in future patient trials, by ensuring maximum exposure of the drug to the tumor site."
James Nathanielsz, Chief Executive Officer of Propanc Health Group, said, "We believe this will help us to improve the results already observed in a Compassionate Use Study conducted by Dr Kenyon at the Dove Clinic (UK). We were able to extend life in a number of terminally ill patients, free from the serious side effects normally observed during conventional treatment methods."
(0)
(0)
